EURONEXT-BRU$NYXH
Nyxoah SA · Q2 2025 earnings
Q2 2025 earnings · · Investor relations
Briefing
Nyxoah Q2 2025: FDA approves Genio as revenue rises 74% to €1.3M ahead of U.S. launch
Nyxoah SA reported second-quarter 2025 revenue of €1.3 million, up 74% from €0.8 million in Q2 2024, as the company received FDA Pre-Market Approval for its Genio hypoglossal neurostimulation system — the first and only bilateral therapy approved in the U.S. for obstructive sleep apnea. Gross margin was 63.4% on cost of goods sold of €490,000. The company posted a Q2 net loss of €20.6 million as R&D spending rose to €10.1 million and SG&A reached €10.7 million amid commercial launch preparations. Cash, cash equivalents and financial assets were €43.0 million at June 30, 2025, down from €63.0 million at March 31. Nyxoah began executing its U.S. commercial strategy with its commercial team in place following the historic FDA approval on August 8, 2025.
- Q2 revenue €1.3M (+74% YoY); gross margin 63.4%.
- FDA PMA approved for Genio — first bilateral hypoglossal neurostimulation therapy in U.S.
- Q2 net loss €20.6M; R&D €10.1M and SG&A €10.7M as launch costs ramp.
- Cash and financial assets €43.0M at June 30 vs €63.0M at March 31.
- U.S. commercial launch underway following August 8 FDA approval.
Headline financials
Revenue & EPS history
Nyxoah SA · Revenue · Quarterly
€6.4M
Revenue by segment
Nyxoah SA · €6.4M total across 2 segments · Q1 2026
- United States€4.3M—67.2%
- International€2.1M—32.8%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 13 quarterly earnings reports · overlaid with Q2 2025
-0.7%
Avg return
Earnings day
+0.6%
Avg return
5 days after
-6.0%
Avg return
30 days after
36%
5 / 14 earnings
Positive
+16.0%
Q1 2024
Best reaction
-13.1%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.4% | -9.0% | -50.4% | |
| Q2 2024 | +3.8% | +7.6% | -5.6% | |
| Q1 2024 | +16.0% | +14.1% | -9.3% | |
| Q4 2023 | -13.1% | +1.2% | -22.8% | |
| Q3 2023 | -11.6% | -7.2% | -15.7% | |
| Q2 2023 | -1.2% | +2.1% | +7.0% | |
| Q1 2023 | -3.3% | -4.9% | +0.6% | |
| Q4 2022 | +4.2% | +1.6% | +54.6% | |
| Q3 2022 | +0.8% | +1.7% | -9.2% | |
| Q2 2022 | +1.5% | +0.8% | -22.5% | |
| Q1 2022 | -3.2% | -9.5% | -4.4% | |
| Q4 2021 | -2.9% | -5.7% | -12.5% | |
| Q3 2021 | +0.0% | +4.3% | -13.5% | |
| Q2 2021 | +0.0% | +11.5% | +20.1% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro